Pre-earnings options volume in Vertex is normal with calls leading puts 7:4. Implied volatility suggests the market is anticipating a move near ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Vertex Pharmaceuticals Incorporated VRTX reported mixed results for its fourth quarter on Monday. The company posted ...

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...

Adjusted earnings of $1.04 billion, or $3.98 per share, fell from $1.1 billion, or $4.20 per share, a year earlier, slightly short of estimates. Vertex pointed to an increase in operating ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations , with sales up 15.7% year on year to $2.91 billion. The company ...

For Q4, Vertex (NASDAQ:VRTX) reported non-GAAP EPS of $3.98 on net product revenue of $2.91B. Analysts, on average, had been expecting non-GAAP EPS of $4.02 on revenue of $2.78B. Looking ahead ...

Vertex's non-GAAP EPS decrease to $3.98, from $4.20 in the previous year, underscores these cost pressures. Expenses from the Alpine acquisition also affected net income and remain a potential ...